

Instrumental Analysis of some Nitrogenous Compounds

Thesis Presented

Taghreed Abd El- Fattah Mohamed

B.Pharm. Sci. Cairo University 1988

Diploma of Quality Assurance 2000

Diploma of Hospital Pharmacy 2002

**For the Degree of Doctor of Philosophy
In Pharmaceutical Sciences
“Analytical Chemistry”**

Under the Supervision of

Prof. Dr. Laila El Sayed Abd El-Fattah

**Professor of Analytical Chemistry
Faculty of Pharmacy
Cairo University**

Prof. Dr. Elham Anwer Taha

**Professor of Analytical Chemistry,
Head of Analytical Chemistry Department,
National Organization for Drug Control and
Research (NODCAR)**

**Department of Analytical Chemistry
Faculty of Pharmacy
Cairo University (2010).**

ACKNOWLEDGEMENT

All my praise, gratitude and deep thanks to ***ALLAH***, who enabled me to complete this work. I would like to express my deep thanks and gratitude to my main supervisor ***PROF. DR. LAILA EL-SAYED ABD EL-FATTAH, PROFESSOR OF ANALYTICAL CHEMISTRY, FACULTY OF PHARMACY, CAIRO UNIVERSITY***, for suggesting the point and plan of this study, for her valuable instructions helpful advice, beneficial discussions, generous assistance and enthusiastic guidance through the whole work. I have the honor and pleasure to be under her supervision.

All my thanks are not enough to express my feeling of sincere gratitude to ***DR. ELHAM ANWER TAHA, HEAD OF RAW MATERIALS, AND PROFESSOR OF ANALYTICAL CHEMISTRY, NATIONAL ORGANIZATION FOR DRUG CONTROL AND RESEARCH***, for her continuous encouragement, beneficial discussions, sincere help offered and for providing all the facilities during the work.

My special thanks to my colleagues and staff members in Raw Materials Department, National Organization for Drug Control and Research, for their friendly cooperation.

My deepest thanks and appreciation to my ***MOTHER***, for her assistance and support through out the difficult times during all stages of the work. I thank her very much.

Also I would like to thank my daughter ***GHADA*** and my son ***AMR***, for bearing with me during this study patience and understand.

Taghreed Abd El Fattah

تحليل ألى لبعض المركبات النيتروجينية

رسالة مقدمة من

الصيدلانية / تغريد عبدالفتاح محمد

بكالوريوس كلية الصيدلة جامعة القاهرة 1988

دبلومة/رقابة و تأكيد جودة 2000

دبلومة / صيدله مستشفيات 2002

للحصول على درجة / دكتوراه الفلسفة فى العلوم الصيدلانية

(الكيمياء التحليلية)

تحت اشراف

الأستاذة الدكتورة/ لىلى السيد عبدالفتاح

أستاذ الكيمياء التحليلية

كلية الصيدلة- جامعة القاهرة

الأستاذة الدكتورة / الهام انور طه

أستاذ الكيمياء التحليلية

رئيس شعبة الكيمياء التحليلية

الهيئة القومية للرقابة و البحوث الدوائية

(NODCAR)

قسم الكيمياء التحليلية

كلية الصيدلة

جامعة القاهرة 2010

CONTENTS

Preface

Summary

PART ONE

General Introduction		Page
1.0.	Introduction -----	1
2.0	Studied compounds -----	6
2.1.	Amlodipine besylate, (AM) -----	6
2.2.	Dobutamine Hydrochloride,(DO) -----	12
2.3.	Carvedilol,(CA) -----	18
2.4.	Acrivastine, (AC) -----	24

PART TWO

**Fluorimetric Determination of Amlodipine Besylate,
Dobutamine Hydrochloride and Carvedilol in Drug
Substances, Drug Products and in Spiked Human
Plasma.**

1.0.	Introduction of fluorimetric methods -----	29
-------------	---	-----------

Section A

Stability-indicating fluorimetric methods for the determination of Amlodipine Basalt in Drug Substance, Drug product and in Spiked Human Plasma.

1.0.	Introduction -----	34
2.0.	Experimental -----	34
2.1.	Apparatus -----	34
2.2.	Samples -----	35
2.3.	Materials and reagents -----	35
2.4.	Stock solutions -----	36
2.5.	Working standard solutions -----	37
2.6.	Procedures -----	37
2.7.	Method validation -----	42
2.7.1.	Linearity -----	42
2.7.2.	Accuracy -----	43
2.7.3.	Precision -----	43
2.7.4.	Specificity -----	43
2.7.5.	Robustness -----	44
2.7.6.	Application on drug product -----	44
2.7.7.	Standard addition technique -----	44
2.8.	Application of the proposed method to the analysis of amlodipine besylate in spiked plasma -----	44
3.0.	Results and discussion -----	45

Section B

Fluorimetric Determination of Dobutamine Hydrochloride in Drug Substance, Drug Product, and in Spiked Human Plasma using Organized Media.

1.0.	Introduction -----	76
2.0.	Experimental -----	76
2.1.	Apparatus -----	76
2.2.	Samples -----	76
2.3.	Materials and reagents -----	77
2.4.	Stock solutions -----	77
2.5.	Working standard solutions -----	77
2.6.	Procedures -----	77
2.7.	Method validation -----	79
2.7.1.	Linearity -----	79
2.7.2.	Accuracy -----	80
2.7.3.	Precision -----	80
2.7.4.	Specificity -----	80
2.7.5.	Robustness -----	80
2.7.6.	Application on drug product -----	81
2.7.7.	Standard addition technique -----	81
2.8.	Application of the proposed method to the analysis of dobutamine hydrochloride in spiked plasma -----	81
3.0.	Results and discussion -----	82

Section C

Quantitative Determination of Carvedilol by Fluorescence Labeling using 5- Dimethylaminonaphthalene-1- Sulphonyl Chloride.

1.0.	Introduction -----	99
2.0.	Experimental -----	99
2.1.	Apparatus -----	99
2.2.	Samples -----	99
2.3.	Materials and reagents -----	100
2.4.	Stock solutions -----	100
2.5.	Working standard solutions -----	100
2.6.	Procedures -----	100
2.7.	Method validation -----	102
2.7.1.	Linearity -----	102
2.7.2.	Accuracy -----	102
2.7.3.	Precision -----	103
2.7.4.	Robustness -----	103
2.7.5.	Application on drug product -----	103
2.7.6.	Standard addition technique -----	104
2.8.	Application of the proposed method to the analysis of carvedilol in spiked plasma -----	104
3.0.	Results and discussion -----	104

PART THREE

Spectrophotometric Determination of Amlodipine besylate, Dobutamine Hydrochloride, Carvedilol, and Acrivastine in Drug Substance and Drug Product.

Section A

Spectrophotometric determination of amlodipine besylate, dobutamine hydrochloride, and carvedilol using p-dimethylaminocinnamaldehyde (p- DAC).

1.0.	Introduction -----	120
2.0.	Experimental -----	120
2.1.	Apparatus -----	120
2.2.	Samples -----	120
2.3.	Materials and reagents -----	120
2.4.	Stock solutions -----	121
2.5.	Working standard solutions -----	121
2.6.	Procedures -----	121
2.7.	Method validation -----	123
2.7.1.	Linearity -----	123
2.7.2.	Accuracy -----	123
2.7.3.	Precision -----	124
2.7.4.	Robustness -----	124
2.7.5.	Application on drug products -----	124
2.7.6.	Standard addition technique -----	125
3.0.	Results and discussion -----	125

Section B

Ratio Derivative Spectrophotometric ¹DD Method for Determination of Dobutamine HCl in presence of its impurity (Dopamine HCl).

1.0.	Introduction -----	142
2.0.	Experimental -----	142
2.1.	Apparatus -----	142
2.2.	Samples -----	142
2.3.	Materials and reagents -----	142
2.4.	Stock solutions -----	143
2.5.	Working standard solutions -----	143
2.6.	Procedures -----	144
2.7.	Method validation -----	144
2.7.1.	Linearity -----	144
2.7.2.	Accuracy -----	145
2.7.3.	Precision -----	145
2.7.4.	Specificity -----	145
2.7.5.	Application on drug product -----	146
2.7.6.	Standard addition technique -----	146
3.0.	Results and discussion -----	146

Section C

Spectrophotometric Determination of Acrivastine in Drug Substance, Drug Product and in Presence of its Degradants via Ion-pair Formation with Methyl Orange.

1.0.	Introduction -----	155
2.0.	Experimental -----	155
2.1.	Apparatus -----	155
2.2.	Samples -----	155
2.3.	Materials and reagents -----	155
2.4.	Stock solutions -----	156
2.5.	Procedures -----	158
2.6.	Method validation -----	160
2.6.1.	Linearity -----	160
2.6.2.	Accuracy -----	160
2.6.3.	Precision -----	160
2.6.4.	Specificity -----	161
2.6.5.	Robustness -----	161
2.6.6.	Application on drug product -----	161
2.6.7.	Standard addition technique -----	161
3.0.	Results and discussion -----	162

PART FOUR

Stability-Indicating Chromatographic Methods for the Determination of Dobutamine Hydrochloride and Acrivastine.

Section A

Stability- Indicating TLC Densitometric Method for the Determination of Dobutamine HCl.

1.0.	Introduction -----	178
2.0.	Experimental -----	178
2.1.	Apparatus -----	178
2.2.	Samples -----	178
2.3.	Materials and reagents -----	178
2.4.	Stock solutions -----	179
2.5.	Working standard solutions -----	179
2.6.	Chromatographic conditions -----	180
2.7.	Method validation -----	180
2.7.1.	Linearity -----	180
2.7.2.	Accuracy -----	181
2.7.3.	Precision -----	181
2.7.4.	Specificity -----	181
2.7.5.	Robustness -----	181
2.7.6.	Application on drug product -----	182
2.7.7.	Standard addition technique -----	182
3.0.	Results and discussion -----	182

Section B

Stability- indicating TLC Densitometric Method for the Determination of Acrivastine

1.0.	Introduction -----	192
2.0.	Experimental -----	192
2.1.	Apparatus -----	192
2.2.	Samples -----	192
2.3.	Materials and reagents -----	192
2.4.	Stock solutions -----	193
2.5.	Chromatographic conditions -----	194
2.6.	Method validation -----	194
2.6.1.	Linearity -----	194
2.6.2.	Accuracy -----	195
2.6.3.	Precision -----	195
2.6.4.	Specificity -----	195
2.6.5.	Robustness -----	195
2.6.6.	Application on drug product -----	196
2.6.7.	Standard addition technique -----	196
3.0.	Results and discussion -----	196

Section C

Kinetic Study on Degradation of Acrivastine by TLC Method

1.0.	Introduction -----	211
2.0.	Experimental -----	211
2.1.	Apparatus -----	211
2.2.	Samples -----	211
2.3.	Materials and reagents -----	211
2.4.	Chromatographic conditions -----	212
2.5.	Kinetic studies -----	212
2.6.	pH-rate profile -----	213
3.0.	Results and Discussion -----	214

PART FIVE

General Discussion -----	222
Reference -----	232
Arabic Summary -----	1

List of Figures

No		Page
1	Effect of solvents on the fluorescence intensity of the native fluorescence of amlodipine besylate ($12\mu\text{gml}^{-1}$).	58
2	Excitation and emission spectra of: The native fluorescence of AM ($4\mu\text{gml}^{-1}$) in water. The reaction product of AM ($4\mu\text{gml}^{-1}$) and 0.5-ml (1.33% w/v) of AlCl_3 . The reaction product of AM ($4\mu\text{gml}^{-1}$) and 2-ml (1.5 % w/v) of ZnSO_4 . The oxidative degradant of AM ($6\mu\text{gml}^{-1}$). The acid and alkaline degradants of AM ($4\mu\text{gml}^{-1}$).	59
3	Effect of volume of 1.33% w/v of aluminum chloride solution, and 1.5% w/v of zinc sulfate solution on the fluorescence intensity of Al^{3+} -amlodipine besylate ($3\mu\text{gml}^{-1}$) and Zn^{2+} -amlodipine besylate ($6\mu\text{gml}^{-1}$) reaction products.	60
4	Effect of different pH on the fluorescence intensity of Al^{3+} -amlodipine besylate ($3\mu\text{gml}^{-1}$) and Zn^{2+} -amlodipine besylate ($6\mu\text{gml}^{-1}$) reaction products.	60
5	Effect of volume of phthalate buffer pH 6 and McIlvaine buffer pH 4 on fluorescence intensity of Al^{3+} -amlodipine ($3\mu\text{gml}^{-1}$) and Zn^{2+} -amlodipine ($6\mu\text{gml}^{-1}$) reaction products.	61
6	Effect of time on fluorescence intensity of Al^{3+} - amlodipine ($3\mu\text{gml}^{-1}$) and Zn^{2+} -amlodipine ($6\mu\text{gml}^{-1}$) reaction products.	61
7	Effect of solvents on the fluorescence intensity of Al^{3+} -amlodipine ($4\mu\text{gml}^{-1}$) and Zn^{2+} -amlodipine ($6\mu\text{gml}^{-1}$) reaction products.	62
8	Linearity of the fluorescence intensity of the native of amlodipine besylate ($1.0\text{-}12.0\mu\text{gml}^{-1}$), Al^{3+} -amlodipine besylate ($0.2\text{-}4.0\mu\text{gml}^{-1}$) and Zn^{2+} -amlodipine besylate ($0.2\text{-}8.0\mu\text{gml}^{-1}$) reaction products.	62
9	Stoichiometry of the reaction between amlodipine besylate and aluminum chloride adopting Job's of continuous variation method using 0.5×10^{-3} M solutions.	63

10	Stoichiometry of the reaction between amlodipine besylat and zinc sulfate adopting Job's of continuous variation method using 0.5×10^{-3} M solutions.	63
11	Effect of different surfactants on the fluorescence intensity : of Al^{3+}-amlodipine besylate ($3\mu\text{gml}^{-1}$) reaction product. of Zn^{2+}-amlodipine besylate ($2\mu\text{gml}^{-1}$) reaction product.	64
12	Excitation and emission spectra: The native fluorescence of AM ($4\mu\text{gml}^{-1}$) in water. The reaction product of AM ($4\mu\text{gml}^{-1}$) and 0.5-ml (0.1M) of AlCl_3 and 2 ml (10 mM) of SDS.	64
13	Effect of concentration of SDS on the fluorescence intensity of Al^{3+}-amlodipine besylate- SDS ($2\mu\text{gml}^{-1}$) reaction product.	65
14	Linearity of the fluorescence intensity of Al^{3+}- amlodipine besylate- SDS reaction product to the corresponding concentration of amlodipine besylate (0.1-$6.0\mu\text{gml}^{-1}$).	65
15	Excitation and emission spectra of the native of AM ($12\mu\text{gml}^{-1}$) in water. Excitation and emission spectra of the reaction of AM ($4\mu\text{gml}^{-1}$) and 3ml (0.2% w/v) FeCl_3.	66
16	Effect of volume of 0.2% w/v FeCl_3 solution on the fluorescence intensity of amlodipine besylate ($12\mu\text{gml}^{-1}$)-FeCl_3 reaction product.	67
17	Effect of solvents on the fluorescence intensity of Fe^{3+}- amlodipine besylate ($12\mu\text{gml}^{-1}$) reaction product.	67
18	Linearity of the decrease in fluorescence intensity of the reaction product between amlodipine besylate and FeCl_3 (1.0-$20.0\mu\text{gml}^{-1}$).	68
17	Effect of solvents on the fluorescence intensity of Fe^{3+}- amlodipine besylate ($12\mu\text{gml}^{-1}$) reaction product.	67
18	Linearity of the decrease in fluorescence intensity of the reaction product between amlodipine besylate and FeCl_3	68